A higher proportion of cancers treated with trastuzumab alone (9/17, 59%) showed a decrease in p-AKT levels, whereas 2/9 (22.2%) tumours treated with trastuzumab and lapatinib showed decreased p-AKT post-treatment. This evidence concerns the gene AKT1 and neoplasm.